Money is cheap and, with the Fed apparently re-embarking on an easing course, it will be getting even cheaper. This is a negative for your savings account. On the flip side, though, borrowing is not expensive — personal and corporate alike. This historically low cost of money (i.e. interest rates) has been a factor in the surge of merger and acquisition (M&A) activity over the past few years. Last year, for instance, the volume of M&A transactions jumped 16% globally from 2017 to $4.1 trillion. One of the recent standouts here is biopharma. The need to supplement or replace revenue… Read More
Money is cheap and, with the Fed apparently re-embarking on an easing course, it will be getting even cheaper. This is a negative for your savings account. On the flip side, though, borrowing is not expensive — personal and corporate alike. This historically low cost of money (i.e. interest rates) has been a factor in the surge of merger and acquisition (M&A) activity over the past few years. Last year, for instance, the volume of M&A transactions jumped 16% globally from 2017 to $4.1 trillion. One of the recent standouts here is biopharma. The need to supplement or replace revenue streams from expiring patents, consolidation, rising stock prices (which equals more equity that can be used as a takeover currency) are some of the reasons pharmaceutical and biotech companies, large and small, continue to merge. It’s eat or get eaten out there. —Recommended Link— Life-and-death investing. At the office, we call them “essential-service” stocks. Because people don’t just want what they sell, they need it. Nobody is going to go without air conditioning in Arizona. It can be a matter of life and death. And try spending a winter in North Dakota with no heat. Read More